A systematic review and meta-analysis of the prevalence, incidence, and predictors of atrial fibrillation in cardiac sarcoidosis

• Published in: International journal of cardiology 2023-11, Vol.391, p.131285-131285, Article 131285
• Main Authors: Sama, Carlson, Fongwen, Noah T., Chobufo, Muchi Ditah, Hamirani, Yasmin S., Mills, James D., Roberts, Melissa, Greathouse, Mark, Zeb, Irfan, Kazienko, Brian, Balla, Sudarshan
• Format: Article
• Language: English
• Subjects: Atrial arrhythmias; Atrial fibrillation; Cardiac sarcoidosis; Outcomes; Predictors
• ISSN: 0167-5273; 1874-1754
• DOI: 10.1016/j.ijcard.2023.131285

The occurrence of atrial arrhythmias, in particular, atrial fibrillation (AF) in patients with cardiac sarcoidosis (CS) are of growing interest in the field of infiltrative cardiomyopathies. Via a systematic review with meta-analysis, we sought to synthesize data on the prevalence, incidence, and predictors of atrial arrhythmias as well as outcomes in patients with CS. PubMed/Medline, Web of Science, and Scopus were systematically queried from inception until April 26th, 2023. Using the random-effects model, separate plots were generated for each effect size assessed. From a total of 8 studies comprising 978 patients with CS, the pooled summary estimates for the prevalence of AF was 23% (95% CI: 13%–34%). Paroxysmal AF was the most common subtype of AF (83%; 95% CI: 77%–90%), followed by persistent AF (17%; 95% CI: 10%–23%). In 9 studies involving 545 patients with CS, the pooled incidence of AF was estimated at 5%, 13.1%, and 8.9% at  4 years of follow-up respectively, with an overall cumulative incidence of 10.6% (95% CI: 4.9%–17.8%) over a 6-year follow-up period. Increased left atrial size and atrial 18F-fluorodeoxyglucose uptake were identified as strong independent predictors for the development of atrial arrhythmias on qualitative synthesis. The burden of AF and related arrhythmias in CS patients is considerable. This necessitates close follow-up and predictive risk-stratification tools to guide the initiation of appropriate strategies, including therapeutic interventions for prevention of AF-related embolic phenomenon, especially in those with known clinical predictors. •There is a high burden of AF in patients with cardiac sarcoidosis (CS)•Paroxysmal atrial fibrillation (AF) is the most common subtype of AF, followed by persistent AF•Incident rate of AF appears to double after the first two years of follow-up, then becomes relatively stable thereafter.•Increased left atrial size and atrial 18F-FDG uptake are strong predictors for the development of atrial arrythmias in patients with CS.•CS patients with AF are at higher risk for adverse outcomes than CS patients without AF